Print Page | Sign In | Join Today
News & Press: New Members

ZielBio

Tuesday, November 19, 2019  
Share |
ZielBio is an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. ZielBio has a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind™. ZielBio closed a Series A financing round in September, 2019.

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected